CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company ...

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end ...

Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027.

Explore Fulcrum Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for FULC. Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending ...

Fulcrum obtained all worldwide development and commercialisation rights for losmapimod, as well as existing drug substance and drug product materials for use in its clinical trials. FSHD is one of ...